Literature DB >> 2569325

Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.

S P Cole1, H F Downes, M L Slovak.   

Abstract

We have examined the ability of eight compounds to enhance adriamycin (ADM) sensitivity of two human tumour cell lines (a small cell lung cancer cell line, NCI-H69, and a fibrosarcoma cell line, HT1080) and their multidrug-resistant variants. The resistant cell lines (H69AR and HT1080/DR4) do not overexpress P-glycoprotein. Verapamil, nicardipine, perhexiline maleate, chloroquine, tamoxifen, clomiphene, prenylamine and trifluoperazine were tested alone and in combination with ADM for their cytotoxic effects. No major differences in sensitivity between the parent and resistant cell lines were noted when these agents were tested alone, except for HT1080/DR4 cells which exhibited a slight collateral sensitivity to nicardipine and H69AR cells which showed cross-resistance to chloroquine and clomiphene. When the chemosensitisers were combined with ADM no enhanced cytotoxicity of either parent cell line was observed. In HT1080/DR4 cells, verapamil showed only a modest dose-dependent chemosensitising effect while the other compounds had no effect. Verapamil and nicardipine enhanced ADM cytotoxicity in H69AR cells slightly but these effects were not dose-dependent. These results demonstrate that the reversal of drug resistance by verapamil and other calcium antagonists in a dose-dependent fashion is not an invariable property of multidrug-resistant tumour cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569325      PMCID: PMC2246955          DOI: 10.1038/bjc.1989.9

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Reduced permeability in CHO cells as a mechanism of resistance to colchicine.

Authors:  V Ling; L H Thompson
Journal:  J Cell Physiol       Date:  1974-02       Impact factor: 6.384

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

3.  Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine.

Authors:  M Inaba; R Fujikura; S Tsukagoshi; Y Sakurai
Journal:  Biochem Pharmacol       Date:  1981-08-01       Impact factor: 5.858

4.  Mode of action of calcium antagonists which alter anthracycline resistance.

Authors:  D Kessel; C Wilberding
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

5.  Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer.

Authors:  D C Tormey; G Falkson; J Crowley; H C Falkson; J Voelkel; T E Davis
Journal:  Am J Clin Oncol       Date:  1982-02       Impact factor: 2.339

6.  Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.

Authors:  A Ramu; Z Fuks; S Gatt; D Glaubiger
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.

Authors:  R Ganapathi; D Grabowski
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

8.  Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line.

Authors:  R T Chlebowski; J B Block; D Cundiff; M F Dietrich
Journal:  Cancer Treat Rep       Date:  1982-01

9.  Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.

Authors:  M L Slovak; G A Hoeltge; W S Dalton; J M Trent
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

10.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

View more
  29 in total

1.  Establishment of two new multi-drug resistant variants of the human tumor line Hep-2.

Authors:  A Redmond; E Law; U Gilvarry; M Clynes
Journal:  Cell Biol Toxicol       Date:  1990-07       Impact factor: 6.691

2.  ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.

Authors:  S Paul; L M Breuninger; K D Tew; H Shen; G D Kruh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21.

Authors:  O Seemann; M Muscheck; M Siegsmund; H Pilch; C T Nebe; J Rassweiler; P Alken
Journal:  Urol Res       Date:  1995

4.  Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.

Authors:  B T Hill; L K Hosking
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells.

Authors:  Kanagaraj Palaniyandi; Qing Zhao; Xiu-Bao Chang
Journal:  Int J Biochem Mol Biol       Date:  2011-04-22

6.  Verapamil prevents the effects of daunomycin on the thermotropic phase transition of model lipid bilayers.

Authors:  J M Canaves; J A Ferragut; J M Gonzalez-Ros
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

Review 7.  ABCG2: a perspective.

Authors:  Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

8.  Replacement of the positively charged Walker A lysine residue with a hydrophobic leucine residue and conformational alterations caused by this mutation in MRP1 impair ATP binding and hydrolysis.

Authors:  Frederic Buyse; Yue-xian Hou; Catherine Vigano; Qing Zhao; Jean-Marie Ruysschaert; Xiu-bao Chang
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

Review 9.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

10.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.